Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism

Abstract

Objective. The aim of this study was to investigate the expression level of soluble LOX-1 (sLOX-1) in the serum of non-small-cell lung cancer (NSCLC) patients and its correlation with lipid metabolism. Methods. 99 inpatients with NSCLC and 81 healthy controls were enrolled in this study. The levels of serum sLOX-1 were compared between the two groups, and the correlation of sLOX-1 with clinicopathological characteristics, blood lipid indices, and carcinoembryonic antigen was analyzed. Results. Compared with the healthy controls, sLOX-1, low-density lipoprotein, triglyceride, and carcinoembryonic antigen in the patients with NSCLC were significantly higher ( p < 0.05), while the expression level of high-density lipoprotein was lower ( p < 0.05). The expression level of sLOX-1 in the serum of patients with healthy controls was positively correlated with low-density lipoprotein (r = 0.72, p < 0.05). The levels of sLOX-1 and low-density lipoprotein in the serum of patients with NSCLC were closely related to the lymph node metastasis, distant metastasis, and TNM stage ( p < 0.05). Compared with a single index, when the sLOX-1 was combined with the CEA, its specificity increased significantly to 97.5% (AUC = 0.995, p < 0.01, 95% CI: 0.989–1.000). Conclusion. sLOX-1 and low-density lipoprotein were overexpressed in the serum of patients with NSCLC, positively correlated, and closely related to the TNM stage and metastasis. This result suggested that lipid metabolic disorders may promote the progression of NSCLC through sLOX-1, which could be a potential serological marker with diagnostic value for NSCLC.

Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients

“…This study suggests that elevated levels of hs-CRP and PTX-3 are risk factors for all-cause mortality, in accordance with previous reports (5,34), whereas sLOX-1 is not. Recently, sLOX-1 was shown to be associated with malignancy (38). During the 2-year follow-up period, we observed two cases of death due to malignancy.…”

LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects

“…LOX-1 receptor and oxLDLs are associated with the development and progression of several pathologies, such as atherosclerosis, obesity, type 2 diabetes, and different cancers [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. Notably, in CaP, we have previously shown that LOX-1 activation by oxLDLs stimulates tumor angiogenesis [ 31 ], epithelial-mesenchymal transition, and tumorigenic potential, being determinant for tumor growth [ 32 ], which could explain why obese patients with CaP progress to more malignant stages in a shorter period of time compared to patients with average weight [ 32 ].…”

“…However, the role of LOX-1 and oxLDLs is not only restricted to pathologies, such as atherosclerosis or endothelial dysfunction, but has also been associated with the progression of chronic pathologies, such as obesity [ 18 , 19 ], type II diabetes mellitus [ 20 , 21 ], and various types of cancer. The role of LOX-1 in cancer is related to the hallmarks of cancer, such as angiogenesis, invasion, metastasis, resisting cell death, and sustained proliferative signaling between others [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ], and has been addressed in depth in several reviews [ 20 , 33 , 34 , 35 , 36 ].…”

Correlation of sLOX-1 and CSF1 with the pathological progression of hypoxic-ischemic encephalopathy in neonatal rats

“…Recent evidence has shown that serum biomarkers like calcium-binding protein B can indicate early-stage HIE and are related to the onset and development of brain injury (6). In addition, soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) can reflect the body's vascular endothelial injury and inflammatory reaction to a certain extent and is a biomarker for a variety of ischemic cardio-cerebrovascular diseases such as acute coronary syndrome and acute cerebral infarction; however, its relationship with hypoxia and ischemia-induced HIE remains unclear (7,8). Furthermore, colony-stimulating factor-1 (CSF1) is shown to reduce neuronal apoptosis and neuroinflammation after HIE-induced brain injury by binding to its receptor CSF1R (9).…”